Table 2.
Summary of the Philadelphia-negative MPN Cases in which TLS Developed.
| Reference | Age | Sex | Diagnosis | Spleen size | Cause of TLS | Treatment for TLS | Outcome |
|---|---|---|---|---|---|---|---|
| 12 | 63 | M | blastic phase PV | spleen enlarged | spontaneously | hydration, allopurinol | died within 2 days |
| 13 | 81 | M | blastic phase PV | massive splenomegaly | 14 days after administration of HU | hemodialysis | recovered |
| 14 | 66 | F | post PV myelofibrosis | massive splenomegaly | splenic irradiation | hydration, allopurinol | recovered |
| 15 | 70 | M | MF | marked splenomegaly | spontaneously | hemodialysis | recovered |
| 16 | 47 | M | PMF | extreme splenomegaly | spontanesouly, hydronephrosis due to stones in bilateral ureteral stones | bilateral ureteral stent, hydration, allopurinol | recovered |
| 17 | 70 | F | post PV myelofibrosis | massive splenomegaly | ruxolitinib withdrawal | hydration, sodium polystyrene sulfonate, intravenous insulin and glucose, rasburicase | recovered |
| This case | 62 | F | post PV myelofibrosis | massibe splenomegaly | ruxolitinib admisistration | hydration, sodium polystyrene sulfonate, intravenous insulin and glucose, allopurinol | recovered |
PV: polycythemia vera, PMF: primary myelofibrosis, HU: Hydroxyurea